Pfizer Inc. (PFE) Stake Increased by Greytown Advisors Inc.

Greytown Advisors Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 43.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,682 shares of the biopharmaceutical company’s stock after acquiring an additional 6,837 shares during the period. Pfizer comprises about 0.6% of Greytown Advisors Inc.’s investment portfolio, making the stock its 24th biggest holding. Greytown Advisors Inc.’s holdings in Pfizer were worth $762,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in PFE. Canada Pension Plan Investment Board grew its stake in shares of Pfizer by 249.6% during the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after acquiring an additional 7,649,416 shares in the last quarter. Marshall Wace North America L.P. grew its stake in shares of Pfizer by 142.8% during the second quarter. Marshall Wace North America L.P. now owns 4,229,547 shares of the biopharmaceutical company’s stock valued at $143,805,000 after acquiring an additional 2,487,663 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Pfizer by 6.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock valued at $1,117,696,000 after acquiring an additional 2,013,835 shares in the last quarter. Sanders Capital LLC grew its stake in shares of Pfizer by 10.8% during the second quarter. Sanders Capital LLC now owns 16,933,077 shares of the biopharmaceutical company’s stock valued at $626,222,000 after acquiring an additional 1,644,036 shares in the last quarter. Finally, Bank of Nova Scotia grew its stake in shares of Pfizer by 325.9% during the first quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock valued at $66,180,000 after acquiring an additional 1,480,258 shares in the last quarter. Institutional investors own 69.90% of the company’s stock.

Shares of Pfizer Inc. (PFE) traded up $0.09 during mid-day trading on Friday, hitting $36.35. 18,584,405 shares of the stock traded hands, compared to its average volume of 12,805,414. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a twelve month low of $30.51 and a twelve month high of $36.78. The company has a market capitalization of $216,671.69, a PE ratio of 14.54, a price-to-earnings-growth ratio of 2.57 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the company posted $0.61 earnings per share. Pfizer’s revenue was up .9% on a year-over-year basis. equities research analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.52%. Pfizer’s dividend payout ratio is currently 79.01%.

In other Pfizer news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock worth $2,118,988 in the last three months. 0.06% of the stock is currently owned by corporate insiders.

Several analysts have recently weighed in on the company. Berenberg Bank restated a “hold” rating and set a $36.00 target price (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Saturday, November 25th. Cowen set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $38.66.

ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.com-unik.info/2017/12/03/pfizer-inc-pfe-stake-increased-by-greytown-advisors-inc.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit